Barclays
BNR

Barclays’s Burning Rock Biotech BNR Stock Holding History

Barclays’s Portfolio BNR Stock Details BNR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-25,941
Closed -$252K – 5230
2023
Q3 		$252K Sell
25,941
-23,920
-48% -$373K ﹤0.01% 3192
2023
Q2 		$1.07M Sell
49,861
-10,897
-18% -$289K ﹤0.01% 2258
2023
Q1 		$1.71M Sell
60,758
-50,931
-46% -$1.53M ﹤0.01% 2307
2022
Q4 		$2.51M Sell
111,689
-22,849
-17% -$521K ﹤0.01% 2097
2022
Q3 		$3.21M Buy
134,538
+55,093
+69% +$1.78M ﹤0.01% 1432
2022
Q2 		$2.31M Buy
+79,445
New +$3.55M ﹤0.01% 1754

Other funds holding BNR

KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
HH
HSG Holding Na, Hong Kong $1.62B AUM 5.91% 1-Year Est. Return

Barclays's BNR Position: Q4 2023 in Review

Barclays sold out of Burning Rock Biotech (BNR) in Q4 2023, closing a stake of 25,941 shares — an estimated $252K sold.

Barclays first reported a position in BNR in Q2 2022 and held it in 6 quarters. The position peaked at $3.21M in Q3 2022. 19 funds tracked by Wall St. Rank hold BNR as of Q4 2023.

  • Barclays reported no remaining Burning Rock Biotech position as of Q4 2023 after selling out during the quarter.
  • Barclays sold 25,941 Burning Rock Biotech shares in Q4 2023, an estimated $252K.
  • Barclays first reported a position in Burning Rock Biotech in Q2 2022 and held it in 6 quarters.
  • Barclays's Burning Rock Biotech position peaked at $3.21M in Q3 2022.
  • 19 funds tracked by Wall St. Rank held Burning Rock Biotech as of Q4 2023.

Based on Barclays's 13F filing for Q4 2023, filed 15 Feb 2024.